Sumitomo Mitsui Trust Group Inc. Trims Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Group Inc. cut its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 6.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,926,084 shares of the biotechnology company's stock after selling 138,966 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 7.10% of Arcturus Therapeutics worth $20,397,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Byrne Asset Management LLC lifted its stake in Arcturus Therapeutics by 89.8% during the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock valued at $31,000 after acquiring an additional 1,365 shares in the last quarter. Virtus ETF Advisers LLC lifted its stake in Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after acquiring an additional 1,132 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Arcturus Therapeutics during the 4th quarter valued at $71,000. National Bank of Canada FI lifted its stake in Arcturus Therapeutics by 639.6% during the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 4,784 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its stake in Arcturus Therapeutics by 22.7% during the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock valued at $186,000 after acquiring an additional 2,036 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARCT. HC Wainwright reiterated a "buy" rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Wells Fargo & Company lowered their target price on Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 10th. Finally, Scotiabank reiterated an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Arcturus Therapeutics has an average rating of "Moderate Buy" and an average target price of $54.00.

Arcturus Therapeutics Stock Performance

ARCT traded up $0.02 during trading hours on Friday, hitting $13.64. The stock had a trading volume of 172,653 shares, compared to its average volume of 421,186. The company's fifty day simple moving average is $12.47 and its 200 day simple moving average is $13.97. Arcturus Therapeutics Holdings Inc. has a 1 year low of $8.04 and a 1 year high of $25.88. The stock has a market cap of $369.78 million, a PE ratio of -5.39 and a beta of 2.27. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.06.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 27.41% and a negative net margin of 47.47%. The company had revenue of $29.38 million during the quarter, compared to analyst estimates of $25.64 million. Equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.